The Biological Axis of Protein Arginine Methylation and Asymmetric Dimethylarginine

Total Page:16

File Type:pdf, Size:1020Kb

The Biological Axis of Protein Arginine Methylation and Asymmetric Dimethylarginine International Journal of Molecular Sciences Review The Biological Axis of Protein Arginine Methylation and Asymmetric Dimethylarginine Melody D. Fulton , Tyler Brown and Y. George Zheng * Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA * Correspondence: [email protected]; Tel.: +1-706-542-0277 Received: 17 June 2019; Accepted: 4 July 2019; Published: 6 July 2019 Abstract: Protein post-translational modifications (PTMs) in eukaryotic cells play important roles in the regulation of functionalities of the proteome and in the tempo-spatial control of cellular processes. Most PTMs enact their regulatory functions by affecting the biochemical properties of substrate proteins such as altering structural conformation, protein–protein interaction, and protein–nucleic acid interaction. Amid various PTMs, arginine methylation is widespread in all eukaryotic organisms, from yeasts to humans. Arginine methylation in many situations can drastically or subtly affect the interactions of substrate proteins with their partnering proteins or nucleic acids, thus impacting major cellular programs. Recently, arginine methylation has become an important regulator of the formation of membrane-less organelles inside cells, a phenomenon of liquid–liquid phase separation (LLPS), through altering π-cation interactions. Another unique feature of arginine methylation lies in its impact on cellular physiology through its downstream amino acid product, asymmetric dimethylarginine (ADMA). Accumulation of ADMA in cells and in the circulating bloodstream is connected with endothelial dysfunction and a variety of syndromes of cardiovascular diseases. Herein, we review the current knowledge and understanding of protein arginine methylation in regards to its canonical function in direct protein regulation, as well as the biological axis of protein arginine methylation and ADMA biology. Keywords: ADMA; PRMT; arginine methylation; nitric oxide; metabolism 1. Introduction Higher-order organisms (e.g., mammals) generally share conserved or similar chemical mechanisms of bimolecular synthesis and metabolism in comparison to lower-order organisms such as prokaryotes. However, a remarkable distinction in the cell biology of higher-order organisms is the complexity of regulation of diverse biological processes such as gene expression, cell cycle, central metabolism, and signal transduction. Sophisticated regulatory mechanisms and networks are present in eukaryotic cells to control or modulate cellular programs for development, differentiation, survival, and adaptation. Such complex mechanisms of regulation include gene fusion/translocation, epigenetics, RNA splicing, protein-protein interaction, protein-nucleic acid association, and post-translational modifications (PTMs) of proteins. Especially, a myriad of post-translational modifications (PTMs) (e.g., phosphorylation, glycosylation, acetylation, methylation) allow for ON/OFF-switching or fine tuning of protein-controlled cellular processes in response to intracellular and extracellular signals. Among the various PTMs, arginine methylation is a widespread PTM that is conserved in all eukaryotic organisms, from yeasts to humans [1–3]. The frequency of the arginine methylome is parallel to the corresponding phosphoproteome and ubiquitylome cells [2]. About 0.5–1% of the total arginine residues in the cellular proteome are methylated and have a slow turnover, likely to confer lasting functional properties to proteins [4,5]. Int. J. Mol. Sci. 2019, 20, 3322; doi:10.3390/ijms20133322 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2019, 20, 3322 2 of 18 Arginine residues can be methylated on the guanidinium nitrogen atoms in three different states—NG-monomethylarginine (Rme1), asymmetric NG,NG-dimethylarginine (Rme2a), G G and symmetricInt. J. Mol. NSci. 2019, N’, 20, -dimethylargininex FOR PEER REVIEW (Rme2s) (Figure1)[ 3,6–8]. Reported results2 of 18 on the stoichiometric abundance of different methylation states, although varying at different degrees, Arginine residues can be methylated on the guanidinium nitrogen atoms in three different generally support that monomethylated arginine is more abundant than dimethylated arginine states—NG-monomethylarginine (Rme1), asymmetric NG,NG-dimethylarginine (Rme2a), and sites in proteins.symmetric Dilworth NG, N’G-dimethylarginine and Barsyte-Lovejoy (Rme2s) analyzed (Figure 1) the [3,6–8]. number Reported of arginine resultsmethylation on the sites in the Phosphositestoichiometric database abundance by of methyl different state, methylatio andn found states, thatalthough arginine varying methylation at different degrees, predominantly exists in thegenerally Rme1 support form that (~84%), monomethylated and the restarginine (~16%) is more are abundant dimethylarginine than dimethylated (including arginine sites Rme2a and in proteins. Dilworth and Barsyte-Lovejoy analyzed the number of arginine methylation sites in the Rme2s) [9]. Guo et al. performed immunoprecipitation and proteomic analysis and found that Rme1 is Phosphosite database by methyl state, and found that arginine methylation predominantly exists in 3–4 fold morethe Rme1 abundant form (~84%), than and Rme2a the rest in (~16%) HCT116 are dimethylarginine cells [10]. In the (includingTrypanosoma Rme2a and brucei Rme2s), it was [9]. reported that methylarginineGuo et al. performed comprised immunoprecipitation approximately and 10% proteomic of the analysis proteome and found [11], that and Rme1 the is proteomic3–4 fold study revealed thatmore theabundant number than ofRme2a peptide in HCT116 fragments cells [10]. containing In the Trypanosoma Rme1 isbrucei 8.2-fold, it was of reported dimethylarginines, that methylarginine comprised approximately 10% of the proteome [11], and the proteomic study and the abundance of Rme2a is 2-fold of Rme2s. A chromatographic analysis of heart/kidney tissue revealed that the number of peptide fragments containing Rme1 is 8.2-fold of dimethylarginines, and hydrolysatesthe showedabundance that of Rme2a Rme2a is level2-fold isof higherRme2s. thanA chromatographic Rme2s by 5–6 analysis fold [of4 ].heart/kidney tissue hydrolysates showed that Rme2a level is higher than Rme2s by 5–6 fold [4]. Figure 1. TheFigure biological 1. The biological axis of axis protein of protein arginine argininemethylation methylation and and formation formation of methylarginine of methylarginine small small molecule metabolites.molecule metabolites. Type Type I, II, I, and II, and III III PRMTs PRMTs catalyzecatalyze the the initial initial monomethylation monomethylation of an arginine of an arginine residue at the terminal guanidinium nitrogen. Subsequently, type I and II can catalyze a second residue at the terminal guanidinium nitrogen. Subsequently, type I and II can catalyze a second arginine methylation reaction to form the asymmetric and symmetric dimethylated arginine residues, arginine methylationrespectively. Protein reaction degradat to formion theof arginine asymmetric methylated and proteins symmetric produces dimethylated the ADMA, L arginine-NMMA, residues, respectively.and ProteinSDMA metabolites. degradation of arginine methylated proteins produces the ADMA, l-NMMA, and SDMA metabolites. 2. PRMTs 2. PRMTs 2.1. PRMT Family in Mammalian Cells Arginine methylation in mammalian cells is catalyzed by the class I, S-adenosyl-l-methionine (SAM or AdoMet)-dependent methyltransferases named protein N-arginine methyltransferases (PRMTs) [12–16]. Mammalian cells have nine PRMTs [17], and all have a highly conserved catalytic Int. J. Mol. Sci. 2019, 20, 3322 3 of 18 Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 3 of 18 core composed2.1. PRMT of aFamily Rossmann-like in Mammalian fold Cells domain that binds SAM and a β-barrel that supports substrate binding (FigureArginine2)[ 18 ].methylation Upon the in initial mammalian binding cells of is SAMcatalyzed and by substrate, the class I, PRMTsS-adenosyl- transferL-methionine the electrophilic methyl group(SAM fromor AdoMet)-dependent SAM to a terminal methyltransferases nitrogen on named the guanidinium protein N-arginine moiety methyltransferases of arginine residues to produce the(PRMTs) monomethylarginine [12–16]. Mammalian cells residue, have nine Rme1 PRMTs [3,6 [17],–8]. and All all PRMTs have a highly will catalyze conserved this catalytic initial methyl core composed of a Rossmann-like fold domain that binds SAM and a β-barrel that supports substrate transfer. Dependingbinding (Figure on 2) whether [18]. Upon or notthe theinitial PRMT binding catalyzes of SAM aand second substrate, methyl PRMTs transfer transfer reaction the defines the type ofelectrophilic PRMT. PRMT1, methyl group -2, -3, from -4 (CARM1), SAM to a terminal -6, and nitrogen -8 are on identified the guanidinium as type moiety I PRMTs, of arginine which produce Rme1 andresidues catalyze to produce a second the reactionmonomethylarginine to produce residu asymmetrice, Rme1 [3,6–8]. dimethylarginine All PRMTs will catalyze residue this (Rme2a) [7]. In contrast,initial PRMT5 methyl andtransfer. PRMT9 Depending produce on whether Rme1 or and not the symmetric PRMT catalyzes dimethylarginine a second methyl residuetransfer (Rme2s), reaction defines the type of PRMT. PRMT1, -2, -3, -4 (CARM1), -6, and -8 are identified as type I which is characteristicPRMTs, which ofproduce type II PRMTsRme1 and [15 ,catalyze19–21]. Whilea second previously reaction misidentifiedto produce asymmetric as a type II PRMT, PRMT7 isdimethylarginine the
Recommended publications
  • The Cross-Talk Between Methylation and Phosphorylation in Lymphoid-Specific Helicase Drives Cancer Stem-Like Properties
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans ARTICLE OPEN The cross-talk between methylation and phosphorylation in lymphoid-specific helicase drives cancer stem-like properties Na Liu1,2,3, Rui Yang1,2, Ying Shi1,2, Ling Chen1,2, Yating Liu1,2, Zuli Wang1,2, Shouping Liu1,2, Lianlian Ouyang4, Haiyan Wang1,2, Weiwei Lai1,2, Chao Mao1,2, Min Wang1,2, Yan Cheng5, Shuang Liu4, Xiang Wang6, Hu Zhou7, Ya Cao1,2, Desheng Xiao1 and Yongguang Tao1,2,6 Posttranslational modifications (PTMs) of proteins, including chromatin modifiers, play crucial roles in the dynamic alteration of various protein properties and functions including stem-cell properties. However, the roles of Lymphoid-specific helicase (LSH), a DNA methylation modifier, in modulating stem-like properties in cancer are still not clearly clarified. Therefore, exploring PTMs modulation of LSH activity will be of great significance to further understand the function and activity of LSH. Here, we demonstrate that LSH is capable to undergo PTMs, including methylation and phosphorylation. The arginine methyltransferase PRMT5 can methylate LSH at R309 residue, meanwhile, LSH could as well be phosphorylated by MAPK1 kinase at S503 residue. We further show that the accumulation of phosphorylation of LSH at S503 site exhibits downregulation of LSH methylation at R309 residue, which eventually promoting stem-like properties in lung cancer. Whereas, phosphorylation-deficient LSH S503A mutant promotes the accumulation of LSH methylation at R309 residue and attenuates stem-like properties, indicating the critical roles of LSH PTMs in modulating stem-like properties. Thus, our study highlights the importance of the crosstalk between LSH PTMs in determining its activity and function in lung cancer stem-cell maintenance.
    [Show full text]
  • Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression
    International Journal of Molecular Sciences Review Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression Guang Yang, Rachel Shi and Qing Zhang * Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; [email protected] (G.Y.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +1-214-645-4671 Received: 6 October 2020; Accepted: 29 October 2020; Published: 31 October 2020 Abstract: Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression. The key molecules of the hypoxia/oxygen-sensing signaling include the transcriptional regulator hypoxia-inducible factor (HIF) which widely controls oxygen responsive genes, the central members of the 2-oxoglutarate (2-OG)-dependent dioxygenases, such as prolyl hydroxylase (PHD or EglN), and an E3 ubiquitin ligase component for HIF degeneration called von Hippel–Lindau (encoding protein pVHL). In this review, we summarize the current knowledge about the canonical hypoxia signaling, HIF transcription factors, and pVHL. In addition, the role of 2-OG-dependent enzymes, such as DNA/RNA-modifying enzymes, JmjC domain-containing enzymes, and prolyl hydroxylases, in gene regulation of cancer progression, is specifically reviewed. We also discuss the therapeutic advancement of targeting hypoxia and oxygen sensing pathways in cancer. Keywords: hypoxia; PHDs; TETs; JmjCs; HIFs 1. Introduction Molecular oxygen serves as a co-factor in many biochemical processes and is fundamental for aerobic organisms to maintain intracellular ATP levels [1,2].
    [Show full text]
  • Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy
    Cancers 2011, 3, 1691-1707; doi:10.3390/cancers3021691 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy Monica Mann 1, Valerie Cortez 1 and Ratna K. Vadlamudi 2,* 1 Department of Cellular and Structural Biology, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; E-Mails: [email protected] (M.M.); [email protected] (V.C.) 2 Department of Obstetrics and Gynecology, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-210-567-4930; Fax: +1-210-567-4958. Received: 4 January 2011; in revised form: 11 March 2011 / Accepted: 25 March 2011 / Published: 29 March 2011 Abstract: Estrogen receptor (ER) signaling plays a key role in hormonal cancer progression. ER is a ligand-dependent transcription factor that modulates gene transcription via recruitment to the target gene chromatin. Emerging evidence suggests that ER signaling has the potential to contribute to epigenetic changes. Estrogen stimulation is shown to induce several histone modifications at the ER target gene promoters including acetylation, phosphorylation and methylation via dynamic interactions with histone modifying enzymes. Deregulation of enzymes involved in the ER-mediated epigenetic pathway could play a vital role in ER driven neoplastic processes. Unlike genetic alterations, epigenetic changes are reversible, and hence offer novel therapeutic opportunities to reverse ERdriven epigenetic changes In this review, we summarize current knowledge on mechanisms by which ER signaling potentiates epigenetic changes in cancer cells via histone modifications.
    [Show full text]
  • Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2010 Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis Ryan Fassnacht Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Physiology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2246 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Ryan C. Fassnacht 2010 All Rights Reserved Molecular Mechanisms Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Ryan Christopher Fassnacht, B.S. Hampden Sydney University, 2005 M.S. Virginia Commonwealth University, 2010 Director: Valeria Mas, Ph.D., Associate Professor of Surgery and Pathology Division of Transplant Department of Surgery Virginia Commonwealth University Richmond, Virginia July 9, 2010 Acknowledgement The Author wishes to thank his family and close friends for their support. He would also like to thank the members of the molecular transplant team for their help and advice. This project would not have been possible with out the help of Dr. Valeria Mas and her endearing
    [Show full text]
  • Interplay Between Epigenetics and Metabolism in Oncogenesis: Mechanisms and Therapeutic Approaches
    OPEN Oncogene (2017) 36, 3359–3374 www.nature.com/onc REVIEW Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches CC Wong1, Y Qian2,3 and J Yu1 Epigenetic and metabolic alterations in cancer cells are highly intertwined. Oncogene-driven metabolic rewiring modifies the epigenetic landscape via modulating the activities of DNA and histone modification enzymes at the metabolite level. Conversely, epigenetic mechanisms regulate the expression of metabolic genes, thereby altering the metabolome. Epigenetic-metabolomic interplay has a critical role in tumourigenesis by coordinately sustaining cell proliferation, metastasis and pluripotency. Understanding the link between epigenetics and metabolism could unravel novel molecular targets, whose intervention may lead to improvements in cancer treatment. In this review, we summarized the recent discoveries linking epigenetics and metabolism and their underlying roles in tumorigenesis; and highlighted the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these abnormalities in cancer. Oncogene (2017) 36, 3359–3374; doi:10.1038/onc.2016.485; published online 16 January 2017 INTRODUCTION metabolic genes have also been identified as driver genes It has been appreciated since the early days of cancer research mutated in some cancers, such as isocitrate dehydrogenase 1 16 17 that the metabolic profiles of tumor cells differ significantly from and 2 (IDH1/2) in gliomas and acute myeloid leukemia (AML), 18 normal cells. Cancer cells have high metabolic demands and they succinate dehydrogenase (SDH) in paragangliomas and fuma- utilize nutrients with an altered metabolic program to support rate hydratase (FH) in hereditary leiomyomatosis and renal cell 19 their high proliferative rates and adapt to the hostile tumor cancer (HLRCC).
    [Show full text]
  • Catalysis by the Jmjc Histone Demethylase KDM4A Integrates Substrate Dynamics, Correlated Motions Cite This: Chem
    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Catalysis by the JmjC histone demethylase KDM4A integrates substrate dynamics, correlated motions Cite this: Chem. Sci., 2020, 11, 9950 † All publication charges for this article and molecular orbital control have been paid for by the Royal Society a a b of Chemistry Rajeev Ramanan, Shobhit S. Chaturvedi, Nicolai Lehnert, Christopher J. Schofield, c Tatyana G. Karabencheva-Christova *a and Christo Z. Christov *a 3 The N -methyl lysine status of histones is important in the regulation of eukaryotic transcription. The Fe(II) and 2-oxoglutarate (2OG) -dependent JmjC domain enzymes are the largest family of histone N3-methyl lysine demethylases (KDMs). The human KDM4 subfamily of JmjC KDMs is linked with multiple cancers and some of its members are medicinal chemistry targets. We describe the use of combined molecular dynamics (MD) and Quantum Mechanical/Molecular Mechanical (QM/MM) methods to study the mechanism of KDM4A, which catalyzes demethylation of both tri- and di-methylated forms of histone Creative Commons Attribution-NonCommercial 3.0 Unported Licence. H3 at K9 and K36. The results show that the oxygen activation at the active site of KDM4A is optimized towards the generation of the reactive Fe(IV)-oxo intermediate. Factors including the substrate binding mode, correlated motions of the protein and histone substrates, and molecular orbital control synergistically contribute to the reactivity of the Fe(IV)-oxo intermediate. In silico substitutions were performed to investigate the roles of residues (Lys241, Tyr177, and Asn290) in substrate orientation. The Lys241Ala substitution abolishes activity due to altered substrate orientation consistent with reported experimental studies.
    [Show full text]
  • Mutant IDH, (R)-2-Hydroxyglutarate, and Cancer
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer Julie-Aurore Losman1 and William G. Kaelin Jr.1,2,3 1Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA; 2Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA Mutations in metabolic enzymes, including isocitrate whether altered cellular metabolism is a cause of cancer dehydrogenase 1 (IDH1) and IDH2, in cancer strongly or merely an adaptive response of cancer cells in the face implicate altered metabolism in tumorigenesis. IDH1 of accelerated cell proliferation is still a topic of some and IDH2 catalyze the interconversion of isocitrate and debate. 2-oxoglutarate (2OG). 2OG is a TCA cycle intermediate The recent identification of cancer-associated muta- and an essential cofactor for many enzymes, including tions in three metabolic enzymes suggests that altered JmjC domain-containing histone demethylases, TET cellular metabolism can indeed be a cause of some 5-methylcytosine hydroxylases, and EglN prolyl-4-hydrox- cancers (Pollard et al. 2003; King et al. 2006; Raimundo ylases. Cancer-associated IDH mutations alter the enzymes et al. 2011). Two of these enzymes, fumarate hydratase such that they reduce 2OG to the structurally similar (FH) and succinate dehydrogenase (SDH), are bone fide metabolite (R)-2-hydroxyglutarate [(R)-2HG]. Here we tumor suppressors, and loss-of-function mutations in FH review what is known about the molecular mechanisms and SDH have been identified in various cancers, in- of transformation by mutant IDH and discuss their im- cluding renal cell carcinomas and paragangliomas.
    [Show full text]
  • Histone Demethylase JMJD6 Regulates Cellular Migration And
    Shen et al. Stem Cell Research & Therapy (2018) 9:212 https://doi.org/10.1186/s13287-018-0949-3 RESEARCH Open Access Histone demethylase JMJD6 regulates cellular migration and proliferation in adipose-derived mesenchymal stem cells Chongyang Shen1,2, Qingli Quan3*, Chuan Yang1, Yueqiang Wen2 and Hong Li1* Abstract Background: Adipose-derived mesenchymal stem cells (ADSCs) have been extensively explored as a promising therapeutic agent due to their differentiation, proliferation and migration abilities. The epigenetic mechanisms that regulate the fate of mesenchymal stem cells (MSCs) have been described in detail. However, the epigenetic modulation of ADSCs proliferation and migration is poorly understood. Methods: The present study examined histone demethylases roles and expression by RT-PCR, as well as through siRNA screening and ChIP-qPCR assay. Cellular proliferation and migration assays were employed in shRNA- mediated JMJD6 knockdown and control ADSCs. PDE1C inhibition studies were conducted to confirm its role in JMJD6-mediated epigenetic regulation of ADSCs. Results: The data demonstrate that the histone demethylase JMJD6 plays a critical role in regulating the proliferation and migration of ADSCs by removing H4R3me2a at the promoter regions of PDEC1 and suppressing PDEC1 expression. Importantly, the depletion of JMJD6 in ADSCs significantly increased cellular proliferation and motility, which was associated with increases in PDE1C expression and decreases in the levels of both cAMP and cGMP. The increase in proliferation and migration was reversed by treatment with a PDE1C inhibitor, suggesting that JMJD6 attenuates the proliferation and migration of ADSCs as an epigenetic regulator and PDE1C partially contributes to the JMJD6-mediated regulation. Conclusions: Taken together, our results indicate for the first time that JMJD6 plays an important role in the regulation of ADSCs proliferation and migration through the modulation of PDE1C expression.
    [Show full text]
  • Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma by Andrea Shergalis
    Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma By Andrea Shergalis A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Medicinal Chemistry) in the University of Michigan 2020 Doctoral Committee: Professor Nouri Neamati, Chair Professor George A. Garcia Professor Peter J. H. Scott Professor Shaomeng Wang Andrea G. Shergalis [email protected] ORCID 0000-0002-1155-1583 © Andrea Shergalis 2020 All Rights Reserved ACKNOWLEDGEMENTS So many people have been involved in bringing this project to life and making this dissertation possible. First, I want to thank my advisor, Prof. Nouri Neamati, for his guidance, encouragement, and patience. Prof. Neamati instilled an enthusiasm in me for science and drug discovery, while allowing me the space to independently explore complex biochemical problems, and I am grateful for his kind and patient mentorship. I also thank my committee members, Profs. George Garcia, Peter Scott, and Shaomeng Wang, for their patience, guidance, and support throughout my graduate career. I am thankful to them for taking time to meet with me and have thoughtful conversations about medicinal chemistry and science in general. From the Neamati lab, I would like to thank so many. First and foremost, I have to thank Shuzo Tamara for being an incredible, kind, and patient teacher and mentor. Shuzo is one of the hardest workers I know. In addition to a strong work ethic, he taught me pretty much everything I know and laid the foundation for the article published as Chapter 3 of this dissertation. The work published in this dissertation really began with the initial identification of PDI as a target by Shili Xu, and I am grateful for his advice and guidance (from afar!).
    [Show full text]
  • The Dynamic Role of Jumonji C Domain Containing Protein 6 in Placental Development and Disease
    The Dynamic Role of Jumonji C Domain Containing Protein 6 in Placental Development and Disease by Sruthi Alahari A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Physiology University of Toronto © Copyright by Sruthi Alahari 2017 i The Dynamic Role of Jumonji C Domain Containing Protein 6 in Placental Development and Disease Sruthi Alahari Doctor of Philosophy Department of Physiology University of Toronto 2017 Abstract Perturbations in oxygen sensing are a defining feature of placental-associated pathologies such as preeclampsia, a serious disorder of pregnancy. Preeclamptic placentae have markedly elevated levels of Hypoxia Inducible Factor 1α (HIF1A), a master regulator of oxygen homeostasis. Mounting evidence implicates a family of Fe2+ and oxygen-dependent Jumonji C domain containing enzymes (JMJDs) as mediators of the epigenetic code and hypoxic gene expression. While several JMJDs are induced in hypoxia, their role in pregnancy remains unclear. The goal of this study was to characterize JMJD6 function in the placenta in physiological and pathological conditions, and unravel its regulatory relationship with von Hippel Lindau tumour suppressor (VHL), a key executor of the cellular hypoxic response. JMJD6 expression inversely correlated with changes in oxygen tension during placental development, while JMJD6 protein and mRNA were significantly elevated in low oxygen and in early-onset preeclamptic (E-PE) placentae. In vitro demethylation assays revealed that optimal JMJD6-dependent demethylation of its histone targets, H3R2me2s and H4R3me2s, occurred in normoxia, and this was impaired in E-PE placentae due to a hypoxia-iron imbalance. In cytotrophoblast cells, JMJD6 is a positive ii regulator of VHL gene expression in normoxia.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0315643 A1 O'garra Et Al
    US 201503 15643A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0315643 A1 O'Garra et al. (43) Pub. Date: Nov. 5, 2015 (54) BLOODTRANSCRIPTIONAL SIGNATURES Publication Classification OF ACTIVE PULMONARY TUBERCULOSS AND SARCODOSIS (51) Int. C. CI2O I/68 (2006.01) (71) Applicants: BAYLOR RESEARCH INSTITUTE, (52) U.S. C. Dallas, TX (US); MEDICAL CPC ............ CI2O I/6883 (2013.01): CI2O I/6886 RESEARCH COUNCIL, Swindon (2013.01); C12O 2600/158 (2013.01); C12O (GB); IMPERIAL COLLEGE 2600/16 (2013.01); C12O 2600/1 18 (2013.01); HEALTHCARE NHS TRUST, London C12O 2600/1 12 (2013.01); C12O 2600/106 (GB) (2013.01) (72) Inventors: Anne O'Garra, London (GB); Chloe (57) ABSTRACT Bloom, London (GB); Matthew Paul The present invention includes a method of determining a Reddoch Berry, London (GB); Jacques lung disease from a patient Suspected of sarcoidosis, tuber F. Banchereau, Montclair, NJ (US); culosis, lung cancer or pneumonia comprising: obtaining a Damien Chaussabel, Bainbridge Island, sample from whole blood of the patient suspected of sarcoi WA (US); Viginia Maria Pascual, dosis, tuberculosis, lung cancer or pneumonia; detecting Dallas, TX (US) expression of (although not exclusive) six or more disease (21) Appl. No.: 14/651,989 genes, markers, or probes selected from SEQID NOS.: 1 to 1446, wherein increased expression of mRNA of upregulated (22) PCT Fled: Dec. 13, 2013 sarcoidosis, tuberculosis, lung cancer and pneumonia mark ers of SEQID NOS.: 1 to 1446 and/or decreased expression (86) PCT NO.: PCT/US2013/075097 of mRNA of downregulated Sarcoidosis, tuberculosis, lung cancer or pneumonia markers of SEQ ID NOS.: 1 to 1446 S371 (c)(1), relative to the expression of the mRNAs from a normal (2) Date: Jun.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]